Bailard’s Xilio Therapeutics XLO Stock Holding History

Bailard’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,617	Closed	-$107K	–	771
2022 Q2	$107K	Buy	+2,617	New	+$138K	﹤0.01%	649

Other funds holding XLO

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bailard's XLO Position: Q3 2022 in Review

Bailard sold out of Xilio Therapeutics (XLO) in Q3 2022, closing a stake of 2,617 shares — an estimated $107K sold.

Bailard first reported a position in XLO in Q2 2022 and held it in 1 quarter. The position peaked at $107K in Q2 2022. 29 funds tracked by Wall St. Rank hold XLO as of Q3 2022.

Bailard reported no remaining Xilio Therapeutics position as of Q3 2022 after selling out during the quarter.
Bailard sold 2,617 Xilio Therapeutics shares in Q3 2022, an estimated $107K.
Bailard first reported a position in Xilio Therapeutics in Q2 2022 and held it in 1 quarter.
Bailard's Xilio Therapeutics position peaked at $107K in Q2 2022.
29 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2022.

Based on Bailard's 13F filing for Q3 2022, filed 18 Oct 2022.